Literature DB >> 17162076

Long-term preservation of dextranomer/hyaluronic acid copolymer implants after endoscopic treatment of vesicoureteral reflux in children: a sonographic volumetric analysis.

Leah P McMann1, Hal C Scherz, Andrew J Kirsch.   

Abstract

PURPOSE: We compared injected volume of dextranomer/hyaluronic acid with sonographic volumes obtained 2 weeks to 36 months postoperatively to evaluate the amount of volume retention with time and to correlate volume retention with voiding cystourethrogram results.
MATERIALS AND METHODS: We retrospectively reviewed sonographic volume measurements of dextranomer/hyaluronic acid implants in children at 2 weeks to 36 months postoperatively. Hydronephrosis and percentage of dextranomer/hyaluronic acid retained at each interval were recorded. Average change in volume at each interval was used to compare volume retention with time. The fraction of dextranomer/hyaluronic acid retained was compared to voiding cystourethrogram at 3 months.
RESULTS: No patient had new or worsened hydronephrosis. Volumetric data were available for 296, 150, 42, 23 and 20 ureters at 2, 3, 6 and 12 weeks, and 24 to 36 months postoperatively, respectively. Percentage of dextranomer/hyaluronic acid retained was 79% at 2, 74% at 3, 70% at 6 and 78% at 12 weeks, and 65% at 24 to 36 months (p >0.05). While there was no significant difference in mean volume retained between cures (74%) and treatment failures (67%), the 94% cure rate with mega-implants (greater than anticipated volume retention) was higher than that with micro-implants (75%) or nonvisualized implants (70%).
CONCLUSIONS: After the initial volume reduction at 2 weeks dextranomer/hyaluronic acid implants remained durable with insignificant volume reduction for up to 36 months postoperatively. Although overall mean volume retention did not correlate with cure, mega-implants were associated with high cure rates and may justify elimination of postoperative voiding cystourethrography.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17162076     DOI: 10.1016/j.juro.2006.08.144

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Injection volumes of dextranomer/hyaluronic acid are increasing in the endoscopic management of vesicoureteral reflux.

Authors:  Mathew D Sorensen; Martin A Koyle; Charles A Cowan; Ismael Zamilpa; Margarett Shnorhavorian; Thomas S Lendvay
Journal:  Pediatr Surg Int       Date:  2010-02-07       Impact factor: 1.827

Review 2.  Diagnosis and management of vesicoureteral reflux in children.

Authors:  Christopher S Cooper
Journal:  Nat Rev Urol       Date:  2009-08-11       Impact factor: 14.432

Review 3.  Surgical management of vesicoureteral reflux in children.

Authors:  Jennifer Sung; Steven Skoog
Journal:  Pediatr Nephrol       Date:  2011-06-22       Impact factor: 3.714

4.  Postoperative ureteral obstruction after endoscopic treatment for vesicoureteral reflux.

Authors:  Jae Min Chung; Chang Soo Park; Sang Don Lee
Journal:  Korean J Urol       Date:  2015-07-01

5.  Endoscopic treatment of vesicoureteral reflux with dextranomer/hyaluronic acid in children.

Authors:  Wolfgang H Cerwinka; Hal C Scherz; Andrew J Kirsch
Journal:  Adv Urol       Date:  2008

6.  New bulking agent for the treatment of vesicoureteral reflux: Polymethylmethacrylate/dextranomer.

Authors:  Sang Woon Kim; Yong Seung Lee; Young Jae Im; Sang Won Han
Journal:  Investig Clin Urol       Date:  2018-04-10

7.  Long-term Outcomes of Endoscopic Anti-reflux Surgery in Pediatric Patients with Vesicoureteral Reflux: Urinary Tract Infection, Renal Scarring, and Predictive Factors for Success.

Authors:  Wonseok Choi; Wook Nam; Chanwoo Lee; Jae Hyeon Han; Jung Hyun Shin; Kun Suk Kim; Sang Hoon Song
Journal:  J Korean Med Sci       Date:  2018-08-08       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.